Skip to content

Nasal Noninvasive NAVA in the Very Low Birth Weight Infant

Nasal Noninvasive NAVA Provides Ventilation in the Very Low Birth Weight Infant

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01785563
Enrollment
40
Registered
2013-02-07
Start date
2013-02-28
Completion date
2018-12-31
Last updated
2022-06-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Inadequate; Pulmonary Ventilation, Newborn, Infant, Very Low Birth Weight

Keywords

NAVA, NIV-NAVA, VLBW, electrical activity of the diaphragm, neural trigger, mechanical ventilation, respiratory distress syndrome

Brief summary

The purpose of this study is to determine if a new type of mechanical ventilation, or breathing machine (called neurally adjusted ventilatory assist or NAVA), will provide additional support to infants who were born prematurely. Investigators are looking to determine if in two hours infants who weighed less than 1500 grams or 3 pounds 5 ounces, will demonstrate a decrease in the amount of carbon dioxide (the gas that humans exhale) dissolved in their blood as compared to prior to starting the study. This will be accomplished by enrolling infants who are stable on their current type of mechanical breathing that provides a constant air flow into the infant. This type of mechanical support helps keep the lungs inflated but does not help remove carbon dioxide. This study will change the type of mechanical support to a type of support called neurally adjusted ventilatory assist or NAVA. This type of mechanical support detects when the infant is breathing in by having electrical sensors on a feeding tube that is placed into the stomach through the nose or mouth. These electrical sensors detect when the diaphragm or the muscle that helps humans breath is trying to take a breath in. When the NAVA ventilator senses the attempt to breath, it provides additional air flow to make the effort of breathing easier. The ventilator will be attached to a tube or cannula that is placed into the infant's nose. After two hours of being on the NAVA ventilator a repeat measure of carbon dioxide in the blood will be performed by taking a small amount of blood from the infant's heel.

Detailed description

Baseline Data Collection: Demographic data: Patient gestational age at delivery, maternal betamethasone therapy, APGAR scores, admission weight, receipt of surfactant administered, age at extubation, time since extubation, current post menstrual age, and current weight. Baseline vitals and ventilation mode: Heart rate, blood pressure, FiO2 (fraction of inspired oxygen), oxygen saturations, transcutaneous partial pressure of carbon dioxide (TCO2) and current mode of ventilation will be recorded four times in a one minute period and the values average to minimize normal variation. Intervention time will be manipulated to begin no later than one hour after the previous feeding, as to minimize interruption of feedings to no greater than 30 minutes. Safety Safety: TCO2 monitor will be attached to the infant and the device will be calibrated according to protocol (reference TCO2 monitor manual). Carbon dioxide diffusion through the skin will be monitored continuously during the intervention (Bromley 08) to avoid periods of hypo or hypercarbia. Edi (electrical activity of the diaphragm) Catheter placement: Edi catheter size will be selected according to infant's weight and length. It will be inserted according to manufacturer's guidelines and adjustments will be made to optimize positioning (reference NAVA manual). NAVA settings: Infants will be maintained on previous level of PEEP (positive end expiratory pressure) or calculated PEEP, rounding up to whole numbers. Initial NAVA level will be determined by starting with an initial NAVA level of 0.5 microvolts/cm of H20. The NAVA level will then be adjusted either by increasing or decreasing to generate a PIP that is a minimum of 8 cm of H2O greater than the current PEEP. Apnea alarm will be set at 5 seconds, which will initiate the NAVA back up setting if no electrical activity is detected by the Edi catheter. Back up NAVA settings will be set with a PIP of 12 cm of H20 greater than current PEEP, respiratory rate of 60 breaths per minute (RR) and inspiratory time of 0.5 seconds. Fraction of inspired oxygen (FiO2) will be adjusted to keep infant's oxygen saturations within previously established clinical parameters. Study Intervention Procedure and Data Collection: At initiation of intervention, and at time 30, 60, 90, and 120 minutes, heart rate (HR), respiratory rate (RR), tidal volume (TV), minute ventilation, FiO2, oxygen saturations, peak Edi and PIP will be recorded four times in a one minute period and the values average to minimize normal variation. Current NAVA settings, TCO2, and blood pressure (BP) will also be recorded. At 60 minutes of intervention if the TCO2 level has not decreased by 5 torr from baseline or has risen, the current NAVA level will be increased by 50%. At 90 minutes if the TCO2 level has not decreased by 5 torr from baseline or has risen; the NAVA level will be increased by 50% from the current level. At the completion of the study (120 minutes or pCO2 outside of established limits) the HR, RR, BP, TV, minute ventilation, FiO2, oxygen saturations, peak Edi and PIP will be recorded four times in a one minute period and the values average to minimize normal variation. A capillary blood gas will be obtained according to standard unit protocol with a warmed heel.

Interventions

DEVICENasal NIV-NAVA

Infants will be placed on nasal NIV-NAVA. Patients initial NAVA level will be set to generate a peak inspiratory pressure that is 8 cm of water greater than their current peak end expiratory pressure. If the infants are on nasal NIV-NAVA at the time of study entry their NAVA level will be increased by 50% rounded up to the nearest 0.1 cm of water per microvolt.

Sponsors

Tarah T Colaizy
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
7 Days to 1 Years
Healthy volunteers
No

Inclusion criteria

* birth weight less than 1,500 grams * Clinical history of respiratory distress syndrome treated with surfactant * Chronological age greater than or equal to seven days * 48 hours post-extubation or greater * Medically stable per primary medical team * Receiving ventilatory support on one of the following systems via nasal pharyngeal tube or nasal prongs:continuous positive airway pressure (CPAP), intermittent mechanical ventilation (IMV), or neutrally adjusted ventilatory assistance (NAVA) * Receiving ventilatory support via high flow nasal cannula if the flow is large enough to provide a positive end expiratory pressure (PEEP) of 6 as defined by PEEP of 6 = 0.68 \* weight (kg) + 0.92 * Capillary blood gas via heel stick within 24 hours that demonstrates a pH of less than or equal to 7.35 and/or a partial pressure of carbon dioxide (pCO2) greater than or equal to 45 mmHg

Exclusion criteria

* Severe congenital abnormalities * Grade III or IV interventricular hemorrhage.

Design outcomes

Primary

MeasureTime frameDescription
Change in Partial Pressure of Carbon Dioxide on Capillary Blood Gas2 hoursdifference between pCO2 (mm Hg) on capillary blood gas obtained within 6 hours of study and immediately after 2 hour study period

Secondary

MeasureTime frameDescription
Change in Fraction of Inspired Oxygen2 hoursdifference between fiO2 at start of study and that at the last measurement timepoint at 120 minutes

Countries

United States

Participant flow

Participants by arm

ArmCount
Nasal Non-Invasive NAVA Group
Infants \< 1500g birthweight, who were intubated and received surfactant at birth, at least 7 days old, and at least 48 hours after endotracheal extubation. Infants must be receiving respiratory support at study entry, including CPAP or non-invasive mechanical ventilation.
27
Total27

Withdrawals & dropouts

PeriodReasonFG000
Overall StudyPhysician Decision10
Overall StudyProtocol Violation2
Overall StudyWithdrawal by Subject1

Baseline characteristics

CharacteristicNasal Non-Invasive NAVA Group
Age, Categorical
<=18 years
27 Participants
Age, Categorical
>=65 years
0 Participants
Age, Categorical
Between 18 and 65 years
0 Participants
Age, Continuous47 days
STANDARD_DEVIATION 29
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants
Race (NIH/OMB)
Asian
1 Participants
Race (NIH/OMB)
Black or African American
4 Participants
Race (NIH/OMB)
More than one race
3 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants
Race (NIH/OMB)
Unknown or Not Reported
0 Participants
Race (NIH/OMB)
White
19 Participants
Region of Enrollment
United States
27 participants
screening capillary blood gas pH7.38 ph units
Sex: Female, Male
Female
12 Participants
Sex: Female, Male
Male
15 Participants

Adverse events

Event typeEG000
affected / at risk
deaths
Total, all-cause mortality
0 / 27
other
Total, other adverse events
0 / 27
serious
Total, serious adverse events
0 / 27

Outcome results

Primary

Change in Partial Pressure of Carbon Dioxide on Capillary Blood Gas

difference between pCO2 (mm Hg) on capillary blood gas obtained within 6 hours of study and immediately after 2 hour study period

Time frame: 2 hours

ArmMeasureValue (MEAN)Dispersion
Nasal Non-Invasive NAVA GroupChange in Partial Pressure of Carbon Dioxide on Capillary Blood Gas0.019 mm HgStandard Deviation 0.037
Secondary

Change in Fraction of Inspired Oxygen

difference between fiO2 at start of study and that at the last measurement timepoint at 120 minutes

Time frame: 2 hours

ArmMeasureValue (MEAN)Dispersion
Nasal Non-Invasive NAVA GroupChange in Fraction of Inspired Oxygen-0.012 percentage of oxygen in inspired gasStandard Deviation 0.0463

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026